growth
Stage
2
Investors
About
Geron is a late-stage clinical biopharmaceutical company developing and potentially commercializing the first-in-class telomerase inhibitor, imetelstat, for the treatment of hematologic myeloid malignancies such as lower-risk myelodysplastic syndromes and myelofibrosis.
Explore Geron's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.